<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To evaluate (99m)Tc-Annexin-V (<z:mp ids='MP_0010594'>TAV</z:mp>) scintigraphy in monitoring radiation-induced apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) patients </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Eleven FL patients (7 female and 4 male; median age, 58 years; range, 42-80 years) with <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">recurrent disease</z:e> underwent <z:mp ids='MP_0010594'>TAV</z:mp> imaging before and 24 hours after the last fraction of the 2 x 2 Gy involved field radiotherapy regimen </plain></SENT>
<SENT sid="2" pm="."><plain>Fine-needle <z:hpo ids='HP_0002835'>aspiration</z:hpo> cytology was performed on 5 consecutive days to determine the optimal time window for <z:mpath ids='MPATH_3'>apoptosis</z:mpath> detection and to confirm the apoptotic nature of the response </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:mp ids='MP_0010594'>TAV</z:mp> scintigraphy (total body studies and SPECT of the irradiated sites) was performed 4 hours after the administration of the radiopharmaceutical </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> uptake was scored in a semiquantitative manner as absent (-) weak (+/-), present (+), or intense (++) with corresponding categories for the cytologic slides </plain></SENT>
<SENT sid="5" pm="."><plain>Response evaluation was performed after 1 week and 4 weeks both in terms of completeness and speed of remission </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Baseline <z:mp ids='MP_0010594'>TAV</z:mp> uptake was absent in 6 and weak in 5 patients </plain></SENT>
<SENT sid="7" pm="."><plain>Sequential cytology indicated that the optimal time period for <z:mpath ids='MPATH_3'>apoptosis</z:mpath> assessment was between 24 and 48 hours after the last fraction of the 2 x 2 Gy regimen </plain></SENT>
<SENT sid="8" pm="."><plain>Baseline cytology was concordant with baseline <z:mp ids='MP_0010594'>TAV</z:mp> in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="9" pm="."><plain>Apoptotic feature appearance (nuclear chromatin condensation, margination and apoptotic body formation) after low-dose irradiation matched the irradiation response in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="10" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> but 1 patient the posttreatment <z:mp ids='MP_0010594'>TAV</z:mp> uptake matched the posttreatment cytology </plain></SENT>
<SENT sid="11" pm="."><plain>In these 10 patients the cytology and <z:mp ids='MP_0010594'>TAV</z:mp> results correlated with the type and <z:hpo ids='HP_0003674'>onset</z:hpo> of the clinical response </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> (99m)Tc-Annexin-V uptake can be increased after 2 x 2 Gy involved field radiotherapy </plain></SENT>
<SENT sid="13" pm="."><plain>This increase was concordant with the appearance of apoptotic <z:mp ids='MP_0000002'>morphology</z:mp> as determined by cytology, and correlated with the clinical outcome </plain></SENT>
<SENT sid="14" pm="."><plain>Apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> can be observed on Day 4 of this regimen and if so predicts a complete remission within 1 week </plain></SENT>
</text></document>